The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity

Emma C. Thomson(University of London), Laura E. Rosen(VIR Biotechnology (United States)), James G. Shepherd(MRC University of Glasgow Centre for Virus Research), Roberto Spreafico(VIR Biotechnology (United States)), Ana Filipe(MRC University of Glasgow Centre for Virus Research), Jason A. Wojcechowskyj(VIR Biotechnology (United States)), Christopher Davis(MRC University of Glasgow Centre for Virus Research), Luca Piccoli(Vir Biotechnology (Switzerland)), David J. Pascall(Glasgow Centre for Population Health), Josh R. Dillen(VIR Biotechnology (United States)), Spyros Lytras(MRC University of Glasgow Centre for Virus Research), Nadine Czudnochowski(VIR Biotechnology (United States)), Rajiv Shah(MRC University of Glasgow Centre for Virus Research), Marcel Meury(VIR Biotechnology (United States)), Natasha Jesudason(MRC University of Glasgow Centre for Virus Research), Anna De Marco(Vir Biotechnology (Switzerland)), Kathy Li(MRC University of Glasgow Centre for Virus Research), Jessica Bassi(Vir Biotechnology (Switzerland)), Áine O’Toole(University of Edinburgh), Dora Pinto(Vir Biotechnology (Switzerland)), Rachel Colquhoun(University of Edinburgh), Katja Culap(Vir Biotechnology (Switzerland)), Ben Jackson(University of Edinburgh), Fabrizia Zatta(Vir Biotechnology (Switzerland)), Andrew Rambaut(University of Edinburgh), Stefano Jaconi(Vir Biotechnology (Switzerland)), Vattipally B. Sreenu(MRC University of Glasgow Centre for Virus Research), Jay C. Nix(Lawrence Berkeley National Laboratory), Ruth F. Jarrett(MRC University of Glasgow Centre for Virus Research), Martina Beltramello(Vir Biotechnology (Switzerland)), Kyriaki Nomikou(MRC University of Glasgow Centre for Virus Research), Matteo Samuele Pizzuto(Vir Biotechnology (Switzerland)), L. Tong(MRC University of Glasgow Centre for Virus Research), Elisabetta Cameroni(Vir Biotechnology (Switzerland)), Natasha Johnson(MRC University of Glasgow Centre for Virus Research), Arthur Wickenhagen(MRC University of Glasgow Centre for Virus Research), Alessandro Ceschi(Ente Ospedaliero Cantonale), Daniel Mair(MRC University of Glasgow Centre for Virus Research), Paolo Ferrari(UNSW Sydney), Katherine Smollett(MRC University of Glasgow Centre for Virus Research), Federica Sallusto(Università della Svizzera italiana), Stephen Carmichael(MRC University of Glasgow Centre for Virus Research), Christian Garzoni(Clinica Luganese Moncucco), Jenna Nichols(MRC University of Glasgow Centre for Virus Research), Massimo Galli(Luigi Sacco Hospital), Joseph Hughes(MRC University of Glasgow Centre for Virus Research), Agostino Riva(Luigi Sacco Hospital), Antonia Ho(MRC University of Glasgow Centre for Virus Research), Malcolm G. Semple(University of Liverpool), Peter Openshaw(Imperial College London), J. Kenneth Baillie(Roslin Institute), The ISARIC4C Investigators(MRC University of Glasgow Centre for Virus Research), Suzannah J. Rihn(Roslin Institute), Samantha Lycett(Roslin Institute), Herbert W. Virgin(Washington University in St. Louis), Amalio Telenti(Vir Biotechnology (Switzerland)), Davide Corti(Vir Biotechnology (Switzerland)), David L. Robertson(VIR Biotechnology (United States)), Gyorgy Snell(VIR Biotechnology (United States))
bioRxiv (Cold Spring Harbor Laboratory)
November 5, 2020
Cited by 118Open Access
Full Text

Abstract

SARS-CoV-2 can mutate to evade immunity, with consequences for the efficacy of emerging vaccines and antibody therapeutics. Herein we demonstrate that the immunodominant SARS-CoV-2 spike (S) receptor binding motif (RBM) is the most divergent region of S, and provide epidemiological, clinical, and molecular characterization of a prevalent RBM variant, N439K. We demonstrate that N439K S protein has enhanced binding affinity to the hACE2 receptor, and that N439K virus has similar clinical outcomes and in vitro replication fitness as compared to wild- type. We observed that the N439K mutation resulted in immune escape from a panel of neutralizing monoclonal antibodies, including one in clinical trials, as well as from polyclonal sera from a sizeable fraction of persons recovered from infection. Immune evasion mutations that maintain virulence and fitness such as N439K can emerge within SARS-CoV-2 S, highlighting the need for ongoing molecular surveillance to guide development and usage of vaccines and therapeutics.


Related Papers

No related papers found

Powered by citation graph analysis